Exelixis, Inc. logo

Exelixis, Inc. (EXEL)

$21.83

Exelixis, Inc. (EXEL) Share Price Forecast
Currently 22 wall-street analysts regularly analyze the financials of Exelixis, Inc. on a frequent basis to provide recommendations along with target share price. 22 analysts offering 12-month price forecasts for Exelixis, Inc. (EXEL) have a share price target of $25. This median of share price forecast represents a 14.52% upside from the latest price of $21.83 as on 27.09.23.

Exelixis, Inc. (EXEL) Price vs Consensus Price Target

Price
Target Price
As per the chart shown above, analysts believe that the Exelixis, Inc. (EXEL) share price will touch around $25 in next 12-months.
Exelixis, Inc. (EXEL) Share Price Forecast v/s Share Price Today
Below is a chart showing the percentage difference between Exelixis, Inc.'s share price and its median forecast price. As on 27.09.23, the difference is -9.04%

Exelixis, Inc. (EXEL): Difference between Current Price & Median Forecasted Price

Difference in Percentage terms
Exelixis, Inc. (EXEL) Share Price : Analyst Recommendation
Based on 22 analysts tracking and researching Exelixis, Inc. (EXEL) share have buy recommendation on an average.

3M Ago1M AgoCurrent
Buy
12
12
12
Outperform
7
7
7
Hold
3
2
2
Underperform
0
0
0
Sell
1
1
1
Exelixis, Inc. (EXEL) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

Moving Average
Price

200 Day Moving Average v/s Current Share Price

Moving Average
Price

FAQs

The latest share price target for Exelixis, Inc. (EXEL) is $25, offered by 22 analysts offering 12-month price forecasts.

Exelixis, Inc. (EXEL) has a maximum of 0.15 upside potential, based on 22 analysts offering 12-month price forecasts.

Based on 22 analysts tracking and researching Exelixis, Inc. (EXEL), 86.36% have a buy recommendation. Remaining 13.64% have either sell or hold recommendations.

The latest share price of Exelixis, Inc. (EXEL) is $21.83 as of 27/09/2023.

19 of total 22 analysts offering stock ratings for Exelixis, Inc. EXEL have recommended buy rating.